| NCT04315298 | Regeneron Pharmaceuticals|Sanofi | COVID-19 | 2020-03-18 | PHASE2|PHASE3 |
| NCT01709578 | Sanofi|Regeneron Pharmaceuticals | Rheumatoid Arthritis | 2012-10 | PHASE3 |
| NCT03564340 | Regeneron Pharmaceuticals | Recurrent Ovarian Cancer|Recurrent Fallopian Tube Cancer|Recurrent Primary Peritoneal Cancer|Recurrent Endometrial Cancer|Endometrial Cancer|Low-grade Serous Ovarian Cancer | 2018-05-21 | PHASE1|PHASE2 |
| NCT05428007 | NYU Langone Health | Melanoma|Unresectable Melanoma | 2023-02-02 | PHASE2 |
| NCT04008069 | Stanford University | Sarcoidosis | 2019-09-03 | PHASE2 |
| NCT04359901 | Westyn Branch-Elliman | COVID | 2020-04-10 | PHASE2 |
| NCT02097524 | Regeneron Pharmaceuticals|Sanofi | Rheumatoid Arthritis | 2014-03 | PHASE1 |
| NCT02373202 | Sanofi|Regeneron Pharmaceuticals | Rheumatoid Arthritis | 2015-02 | PHASE3 |
| NCT04357808 | Maria del Rosario Garcia de Vicu?a Pinedo|Instituto de Investigación Sanitaria Hospital Universitario de la Princesa | Covid-19 | 2020-04-13 | PHASE2 |
| NCT02293902 | Sanofi|Regeneron Pharmaceuticals | Rheumatoid Arthritis | 2014-11 | PHASE3 |
| NCT04386239 | ASST Fatebenefratelli Sacco | COVID19 | 2021-01-01 | EARLY_PHASE1 |
| NCT04324073 | Assistance Publique - H?pitaux de Paris | Corona Virus Infection | 2020-03-27 | PHASE2|PHASE3 |
| NCT04327388 | Sanofi|Regeneron Pharmaceuticals | Corona Virus Infection | 2020-03-28 | PHASE3 |
| NCT04350216 | Instituto de Investigación Marqués de Valdecilla | Rheumatoid Arthritis|Atherosclerosis | 2020-04-30 | PHASE4 |
| NCT02332590 | Sanofi|Regeneron Pharmaceuticals | Rheumatoid Arthritis | 2015-01-28 | PHASE3 |
| NCT01061723 | Sanofi|Regeneron Pharmaceuticals | Ankylosing Spondylitis | 2010-02 | PHASE2 |
| NCT04590326 | Regeneron Pharmaceuticals | Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer|Endometrial Cancer | 2020-12-08 | PHASE1|PHASE2 |
| NCT02017639 | Sanofi|Regeneron Pharmaceuticals | Rheumatoid Arthritis | 2014-01 | PHASE1 |
| NCT03449758 | Sanofi|Regeneron Pharmaceuticals | Rheumatoid Arthritis | 2018-03-05 | PHASE4 |
| NCT07484113 | Stanford University | cGVHD | 2026-05 | PHASE1 |
| NCT03535402 | Gaylis, Norman B., M.D. | Rheumatoid Arthritis | 2018-06-01 | PHASE3 |
| NCT03600805 | Sanofi|Regeneron Pharmaceuticals | Giant Cell Arteritis | 2018-11-20 | PHASE3 |
| NCT03679845 | Massachusetts General Hospital|Regeneron Pharmaceuticals | Morphea, Plaque Form | 2019-09-01 | PHASE1|PHASE2 |
| NCT01042379 | QuantumLeap Healthcare Collaborative | Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer | 2010-03-01 | PHASE2 |
| NCT04357860 | Maimónides Biomedical Research Institute of Córdoba|Junta de Andalucia|Red Andaluza de Ensayos Clínicos en Enfermedades Infecciosas (Red ANCRAID) | SARS-CoV 2|SARS | 2020-04-28 | PHASE2 |
| NCT07154290 | Regeneron Pharmaceuticals | Advanced+Metastatic Non-Small Cell Lung Cancer | 2026-03-18 | PHASE2 |
| NCT03770273 | National Institute of Allergy and Infectious Diseases (NIAID) | Indolent Systemic Mastocytosis | 2019-06-19 | PHASE2 |
| NCT01850680 | Sanofi|Regeneron Pharmaceuticals | Rheumatoid Arthritis | 2013-04 | PHASE1 |
| NCT03414502 | University of Nebraska | Rheumatoid Arthritis | 2007-12-10 | PHASE3 |
| NCT06787612 | Regeneron Pharmaceuticals | Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer | 2025-05-28 | PHASE2 |
| NCT01061736 | Sanofi|Regeneron Pharmaceuticals | Rheumatoid Arthritis | 2010-03 | PHASE2|PHASE3 |
| NCT01217814 | Sanofi|Regeneron Pharmaceuticals | Rheumatoid Arthritis | 2010-11 | PHASE2 |
| NCT07196306 | BayCare Health System | COVID|COVID-19|Corona Virus Infection | 2020-05-07 | PHASE2 |
| NCT05704634 | M.D. Anderson Cancer Center|Regeneron Pharmaceuticals | Lung Cancer | 2023-08-18 | PHASE1 |
| NCT02057250 | Sanofi|Regeneron Pharmaceuticals | RA | 2014-03 | PHASE3 |
| NCT01764997 | Sanofi|Regeneron Pharmaceuticals | Rheumatoid Arthritis | 2013-04 | PHASE3 |
| NCT02404558 | Sanofi|Regeneron Pharmaceuticals | Rheumatoid Arthritis | 2015-05 | PHASE1 |
| NCT05535738 | Wei-Che Ko | Skin Inflammation|Allergic Contact Dermatitis | 2022-11-15 | PHASE2|PHASE3 |
| NCT05638932 | Aetion, Inc. | COVID-19 | 2020-06-16 | |
| NCT07286214 | Sanofi|Regeneron Pharmaceuticals | Polymyalgia Rheumatica | 2026-04-15 | PHASE4 |
| NCT04341870 | Assistance Publique - H?pitaux de Paris | COVID19|SARS-CoV-2 Infection | 2020-04-11 | PHASE2|PHASE3 |
| NCT02991469 | Sanofi|Regeneron Pharmaceuticals | Juvenile Idiopathic Arthritis | 2018-08-09 | PHASE2 |
| NCT02776735 | Sanofi|Regeneron Pharmaceuticals | Juvenile Idiopathic Arthritis | 2016-09-06 | PHASE2 |
| NCT01900431 | Sanofi | Uveitis | 2013-10 | PHASE2 |
| NCT04661527 | Clinica Universidad de Navarra, Universidad de Navarra|Sanofi|Hospital Universitario Infanta Leonor | COVID-19 Drug Treatment | 2020-04-22 | PHASE2 |
| NCT03378219 | Sanofi|Regeneron Pharmaceuticals | Rheumatoid Arthritis -Exposure During Pregnancy | 2018-05-18 | |
| NCT06418529 | Pfizer | Rheumatoid Arthritis | 2024-05-15 | |
| NCT02735707 | UMC Utrecht|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|Intensive Care National Audit & Research Centre|St. Marianna University School of Medicine|Nat Intensive Care Surveillance - MORU|National University Hospital, Singapore | Community-acquired Pneumonia, Influenza, COVID-19 | 2016-04-11 | PHASE3 |
| NCT01118728 | Sanofi|Regeneron Pharmaceuticals | Ankylosing Spondylitis | 2010-06 | PHASE2 |
| NCT04333706 | University of Southern California|National Cancer Institute (NCI) | Breast|Metastatic|Triple Negative|Cancer|Disseminated Tumor Cell | 2020-09-26 | PHASE1|PHASE2 |
| NCT01768572 | Sanofi|Regeneron Pharmaceuticals | Rheumatoid Arthritis | 2013-03 | PHASE3 |
| NCT04134728 | GlaxoSmithKline|IQVIA Pty Ltd | Arthritis, Rheumatoid | 2019-10-31 | PHASE3 |